Conway Capital Management Inc. Purchases Shares of 31,925 Boston Scientific Co. (NYSE:BSX)

Conway Capital Management Inc. bought a new stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The fund bought 31,925 shares of the medical equipment provider's stock, valued at approximately $2,675,000. Boston Scientific makes up 1.3% of Conway Capital Management Inc.'s portfolio, making the stock its 17th largest position.

Several other large investors also recently modified their holdings of the stock. Dunhill Financial LLC lifted its holdings in Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 152 shares during the last quarter. Triad Wealth Partners LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at $26,000. Values First Advisors Inc. bought a new stake in Boston Scientific during the 3rd quarter worth about $28,000. E Fund Management Hong Kong Co. Ltd. bought a new stake in shares of Boston Scientific during the third quarter worth approximately $30,000. Finally, Capital Performance Advisors LLP acquired a new stake in Boston Scientific during the 3rd quarter worth $30,000. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the business's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the transaction, the executive vice president now owns 160,467 shares of the company's stock, valued at $13,639,695. The trade was a 45.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the completion of the sale, the executive vice president now directly owns 29,308 shares of the company's stock, valued at approximately $2,660,580.24. The trade was a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 328,157 shares of company stock worth $27,957,676 over the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Up 1.7 %

Shares of BSX traded up $1.51 during mid-day trading on Tuesday, hitting $90.23. 4,610,782 shares of the company's stock were exchanged, compared to its average volume of 6,002,105. The company has a 50-day simple moving average of $87.50 and a 200 day simple moving average of $81.44. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The company has a market cap of $132.98 billion, a PE ratio of 74.55, a P/E/G ratio of 2.65 and a beta of 0.80. Boston Scientific Co. has a 52 week low of $54.86 and a 52 week high of $91.93.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04. The firm had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company's revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.50 EPS. On average, research analysts forecast that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BSX. Canaccord Genuity Group increased their price target on Boston Scientific from $98.00 to $101.00 and gave the company a "buy" rating in a research note on Monday. Mizuho increased their target price on Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday, October 24th. StockNews.com lowered Boston Scientific from a "buy" rating to a "hold" rating in a research report on Monday, November 4th. BTIG Research increased their price target on shares of Boston Scientific from $84.00 to $93.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Finally, Truist Financial lifted their price objective on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a "buy" rating in a research note on Monday, October 14th. Four investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $93.52.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.